FDA approves Bausch + Lomb, Novaliq dry eye disease drugTherapeuticsThe regulator’s approval makes Miebo the first DED treatment that directly addresses tear evaporation. The drug is expected to hit U.S. markets in the second half of 2023. Read more May 19, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2023/05/Dry-Eye.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-05-19 09:37:452023-05-19 09:38:25FDA approves Bausch + Lomb, Novaliq dry eye disease drug
